Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enterome Raises EUR Five Million in Series A Funding Round

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
Funding enables further development of unique metagenomic technology and solutions for gut microbiota-related diseases affecting a large proportion of world population.

Enterome has announced a first closing of a series A funding round, raising EUR five million. This funding follows a previous seed round that raised EUR 1.5 million from Seventure Partners (Natixis) and INRA Transfert.

The series A round has brought in Seventure and Lundbeckfond Ventures, as new co-lead investors. Seventure is one of the most active European investors in venture capital investing in life sciences and information and communication technologies.

Lundbeckfond Ventures is a pure life science venture fund investing in companies in Europe and the US.

The amount raised will enable Enterome to fulfil several objectives. Firstly, Enterome will validate its proprietary biomarkers and translate them into high value medical diagnostics and to commercialize it as laboratory developed test services in the US and EU.

The company also plans to initiate industrial partnerships (in the pharmaceutical and the nutrition fields) to strengthen its development capabilities.

Enterome’s two lead projects are in non-alcoholic fatty liver disease (NAFLD) and in inflammatory bowel diseases (IBD).

The new management team is highly experienced and made up of a blend of former founders and executives of Fovea Pharmaceuticals (acquired by Sanofi in 2009) and biomarkers specialists. Bernard Gilly was also appointed as the new chairman of the board.

“The series A round investors - Seventure and Lundbeckfond Ventures - were specifically attracted to Enterome due to the unique nature of its technology, the close relationship to INRA and the opportunity to create unique biomarker diagnostic products meeting unmet medical and market needs,” said Pierre Belichard, CEO, Enterome.

Belichard continued, “Research by Enterome’s scientific founders has improved understanding of the human microbiota composition to the point of now allowing development of powerful new biomarkers and associated therapeutics. This technology was elected as one of top five scientific breakthroughs of 2011 by the journal Science.”

The human intestine harbors an incredible number of bacteria, the gut microbiota, encoding 150-fold more genes than the human genome. Each individual has his own personal and unique microbiota, with a large diversity between individuals.

Over the last five years, physicians and researchers have proved the undisputed role of gut microbiota in the development of various diseases, especially metabolic disorders and inflammatory bowel diseases.

These diseases affect 25 per cent of the western world population, with NASH, the most harmful, diagnosed in two to three per cent of the population globally.

Enterome’s technology was developed initially at the INRA (Institut National de la Recherche Agronomique) by Dusko Ehrlich at Jouy-en-Josas, France.

Enterome has entered into a collaboration agreement with INRA, providing the company with exclusive access to discoveries made using this metagenomic platform in selected human pathologies including type II diabetes, liver and bowel diseases.

“Measurement and modulation of the gut microbiota’s role in health and disease presents the opportunity to impact medicine in an entirely new and unexplored way,” said Dusko Ehrlich, scientific founder of Enterome and leader of the metaHIT European consortium.

“We are particularly pleased to see one of our main research assets being translated into a company and financed by an international group of investors,” said Gérard Jacquin, president of INRA Technology Transfer organization. “Enterome is a key element in our Metagenopolis organization, a center for excellence in metagenomics of the human gut microbiota developed at INRA.”

“I am particularly proud to see Enterome developing, helped by the strong and longstanding relationship Seventure has established with INRA,” said Isabelle de Cremoux, CEO of Seventure subsidiary of Natixis.

“We are impressed by the Enterome leadership and are very confident that Enterome will translate this very innovative platform into valuable diagnostic and therapeutic tools,” said Johan Kordel from Lundbeckfond Ventures.

Emmanuelle Porte and Sylvie Hamel, specializing in venture capital and private equity at Nixon Peabody, acted as legal advisors for Enterome in this series A funding round.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos